Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selectins--potential pharmacological targets?

Carsten Kneuer1, Carsten Ehrhardt, Marek W Radomski

  • 1Institute for Pharmacology, Pharmacy and Toxicology, University of Leipzig, An den Tierkliniken 15, Leipzig, Germany.

Drug Discovery Today
|October 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Properties and Preparation of Ethyl Cellulose-Ethanol Gel Sclerotherapy for the Treatment of Vascular Malformations following the 3R Principle.

ACS applied bio materials·2026
Same author

Correction: Fahmy et al. Palladium Nanoparticles Fabricated by Green Chemistry: Promising Chemotherapeutic, Antioxidant and Antimicrobial Agents. <i>Materials</i> 2020, <i>13</i>, 3661.

Materials (Basel, Switzerland)·2026
Same author

Correction: Fahmy et al. PEGylated Chitosan Nanoparticles Encapsulating Ascorbic Acid and Oxaliplatin Exhibit Dramatic Apoptotic Effects against Breast Cancer Cells. <i>Pharmaceutics</i> 2022, <i>14</i>, 407.

Pharmaceutics·2026
Same author

Do co-formulants influence plant protection product genotoxicity?

Regulatory toxicology and pharmacology : RTP·2026
Same author

Quantitative evaluation of genotoxicity data for risk assessment and regulatory decision-making: Time for a paradigm shift.

Environment international·2026
Same author

How the methodology determines the outcome of the in vitro micronucleus assay (OECD TG 487): a comparison of the MicroFlow and the microscopic evaluation approach highlights the impact of cytotoxicity/cytostasis metrics in V79 cells for matrine.

Archives of toxicology·2026

Selectins are key proteins in serious illnesses like cancer and immune diseases. New research explores selectin-targeting therapies, including antibodies and small molecule drugs, for treating these conditions.

Area of Science:

  • Biochemistry and Molecular Biology
  • Immunology
  • Oncology

Background:

  • Selectins, a protein family, are increasingly recognized for their role in pathological conditions.
  • These conditions include cancer metastasis, immunological diseases (asthma, allergy, autoimmune reactions), post-ischemic damage, and transplant failures.
  • While not always the primary cause, selectin involvement makes them attractive therapeutic targets.

Purpose of the Study:

  • To review the latest advancements in therapeutic and diagnostic strategies targeting selectins.
  • To highlight emerging trends in the development of anti-selectin agents and imaging tools.

Main Methods:

  • This review synthesizes recent research on various anti-selectin approaches.
  • Methods discussed include antibody therapies, recombinant counter-receptors, glycomimetics, selectin tolerance induction, and imaging agents.

Related Experiment Videos

Main Results:

  • Significant progress has been made in developing diverse therapeutic modalities targeting selectins.
  • These include antibodies, small molecule antagonists (glycomimetics), and strategies to induce selectin tolerance.
  • Selectin-targeted imaging agents are also emerging for diagnostic applications.

Conclusions:

  • Selectin-targeting strategies represent a promising frontier in treating cancer, immunological disorders, and other selectin-associated pathologies.
  • The development of novel antibodies, antagonists, and imaging agents offers new therapeutic and diagnostic avenues.